Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Nilotinib, Trametinib, and Dabrafenib for the Treatment of BRAF V600 Mutant Metastatic or Unresectable Melanoma

Multiple Cancer Types

This phase I trial is to find out the best dose, possible benefits and/or side effects of nilotinib given together with trametinib and dabrafenib in treating patients with BRAF V600 mutant melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Nilotinib, trametinib, and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nilotinib together with trametinib and dabrafenib may lower the chance of cancer growing or spreading.
Melanoma, Phase I
I
Johnson, Douglas
NCT04903119
VICCMELP2274

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Multiple Cancer Types

The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or
Axitinib), in subjects with advanced renal cell carcinoma.
Kidney (Renal Cell), Phase I
I
Rini, Brian
NCT04522323
VICCUROP2043

Intraoperative identification and stimulation of the ANSA cervicalis.

Head/Neck

Head/Neck
N/A
Kent, David
VICCHN2291

Mohs Reconstruction Decision Making

Dermatologic

Dermatologic
N/A
Patel, Priyesh
VICCDERM22116

Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer Prostate Cancer Risk Clinic (PCRC) Study

Prostate

Prostate
N/A
Tosoian, Jeffrey
VICCURO22121

Descriptive Study of Pain Syndrome in Survivors of Head and Neck Cancer

Head/Neck

Head/Neck
N/A
Kohutek, Zachary
VICC-VDHAN23178

Prospective Observational Trial of a Biodegradable Hyaluronic Acid Spacer in Prostate Cancer Radiotherapy

Prostate

Prostate
N/A
Kirschner, Austin
VICC-VDURO23220

Developing a Trustworthy Multilevel Intervention to Improve Equity in Lung Cancer Screening

Lung

Lung
N/A
Richmond, Jennifer
VICC-VDTHO23221


Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.